Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.

Quentin Chalret du Rieu,Mélanie White-Koning,Laetitia Picaud,Isabelle Lochon,Sabrina Marsili,Laurence Gladieff,Etienne Chatelut,Gwenael Ferron

Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.

2014

Quentin Chalret du Rieu
Mélanie White-Koning
Laetitia Picaud
Isabelle Lochon
Sabrina Marsili
Laurence Gladieff
Etienne Chatelut
Gwenael Ferron

Purpose First, to evaluate the peritoneal (IP), plasma ultrafiltrated (UF) and protein-bound (B) pharmacokinetics (PK) of oxaliplatin after intraperitoneal hyperthermic chemoperfusion (HIPEC) following cytoreductive surgery. Second, to evaluate the relationship between oxaliplatin exposure and observed toxicity.

Keywords:

Population
Organoplatinum Compounds
Peritoneal Neoplasm
Oxaliplatin
Peritoneal cancer
Pharmacokinetics
Toxicity
Surgery
Medicine
in patient
Oncology
Gastroenterology
population pharmacokinetics
cytoreductive surgery
Pharmacology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations